MGMT and central nervous system cancer: Notably, our study revealed a significant correlation between IDH1 wildtype genotype (Fig. 4A), 1p/19p co-deletion (Fig. 4B), and MGMT promoter methylation status (Fig. 4C) in patients with glioma and a high-risk score.